A Phase 3 Two-part Study of the Efficacy and Safety of HLX04-O in Subjects With Wet Age-related Macular Degeneration
Status:
Recruiting
Trial end date:
2023-06-14
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy, safety, tolerability, and pharmacokinetics of HLX04-O
administered monthly, compared with ranibizumab monthly, in participants with neovascular
age-related macular degeneration (nAMD).